B-cell malignancies
Telios Pharma Inc. supports clinical research in B-cell malignancies, with attention to chronic lymphocytic leukemia and small lymphocytic lymphoma. The funded studies also include treatment settings for relapsed/refractory disease and treatment-naïve patient groups.
- Chronic lymphocytic leukemia
- Small lymphocytic lymphoma
- Relapsed/refractory B-cell disease
These trials reflect a therapeutic focus on hematologic cancers where symptom control and disease response remain key clinical priorities.
Myelofibrosis
The sponsor also funds research in myelofibrosis, a chronic myeloproliferative neoplasm associated with progressive marrow and blood-related complications. This area extends the clinical portfolio beyond lymphoid malignancies into broader hematologic disorders.
- Myelofibrosis
- Myeloproliferative neoplasms
- Blood disorder management
Clinical interest in this field centers on conditions with substantial symptom burden and ongoing need for disease-directed therapy.
Indolent systemic mastocytosis
Telios Pharma Inc. is active in studies of indolent systemic mastocytosis, a rare mast cell disorder characterized by persistent systemic symptoms. This area includes research into symptom-focused management for patients living with chronic mast cell–mediated disease.
- Indolent systemic mastocytosis
- Mast cell disorders
- Systemic symptom control
The sponsor’s activity in this domain highlights interest in rare immunologic and hematologic conditions with complex symptom profiles.
Monoclonal mast cell activation syndrome and mast cell activation syndrome
Additional research support extends to monoclonal mast cell activation syndrome and mast cell activation syndrome, both of which involve abnormal mast cell activity and recurring multisystem symptoms. These studies place emphasis on disorders where mediator-driven symptoms can affect daily functioning.
- Monoclonal mast cell activation syndrome
- Mast cell activation syndrome
- Mast cell–mediated symptoms
This therapeutic area broadens the sponsor’s portfolio into rare disease research at the intersection of hematology and immunology.
